Athenex (OTCPK:ATNX.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

ATNX.Q Stoklara Genel Bakış

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. Daha fazla detay

ATNX.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	0/6
Temettüler	0/6

Risk Analizi

Anlamlı bir piyasa değeri yok ( $132K )

Negatif hissedar öz sermayesi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Kazançlar son 5 yılda yılda 7.6% oranında azaldı

+ 1 daha fazla risk

Athenex, Inc. Rakipler

Histogen

OTCPK:HSTO.Q

US$85.4k

Endonovo Therapeutics

OTCPK:ENDV

US$317.5k

Capstone Holding

OTCPK:CAPS

US$504.4k

Yield10 Bioscience

OTCPK:YTEN

US$216.5k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Athenex
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.015
52 Haftanın En Yüksek Seviyesi	US$6.00
52 Haftanın En Düşük Seviyesi	US$0.0003
Beta	0.79
11 Aylık Değişim	52.00%
3 Aylık Değişim	-86.19%
1 Yıllık Değişim	-99.72%
33 Yıllık Değişim	-99.99%
5 Yıllık Değişim	-99.99%
Halka arzdan bu yana değişim	-99.99%

Son Haberler & Güncellemeler

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29

Hissedar Getirileri

	ATNX.Q	US Biotechs	US Pazar
7D	0%	4.0%	2.0%
1Y	-99.7%	18.0%	32.4%

Getiri vs. Endüstri: ATNX.Q geçen yıl % 18 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: ATNX.Q geçen yıl % 32.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is ATNX.Q's price volatile compared to industry and market?
ATNX.Q volatility
ATNX.Q Average Weekly Movement	339.2%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: ATNX.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: ATNX.Q 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 167% dan 339% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2003	275	Johnson Lau	www.athenex.com

Athenex, Inc. Temel Bilgiler Özeti

Athenex'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ATNX.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$131.68k
Kazançlar(TTM)	-US$97.98m
Gelir(TTM)	US$102.82m

0.0x

P/S Oranı

0.0x

F/K Oranı

ATNX.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ATNX.Q gelir tablosu (TTM)
Gelir	US$102.82m
Gelir Maliyeti	US$76.12m
Brüt Kâr	US$26.70m
Diğer Giderler	US$124.68m
Kazançlar	-US$97.98m

Son Raporlanan Kazançlar

Dec 31, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-11.31
Brüt Marj	25.97%
Net Kâr Marjı	-95.29%
Borç/Özkaynak Oranı	-511.7%

ATNX.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

ATNX.Q Stoklara Genel Bakış

Risk Analizi

Athenex, Inc. Rakipler

OTCPK:HSTO.Q

US$85.4k

OTCPK:ENDV

US$317.5k

OTCPK:CAPS

US$504.4k

OTCPK:YTEN

US$216.5k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Athenex prices $30M in stock and warrants offering

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex GAAP EPS, revenue misses estimates

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex to sell its China API business for $19M

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$4.50

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Price target decreased to US$4.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$5.50

Price target increased to US$6.67

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought US$61k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought US$161k worth of stock

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.31

Price target decreased to US$7.50

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Independent Director exercised options to buy US$230k worth of stock.

Consensus EPS estimates increase to -US$1.42

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.